Navigation Links
Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance
Date:12/10/2009

de franchise.

The company anticipates that gross margin as a percent of revenue will be flat to declining. Excluding the effect of foreign exchange rates on international inventories sold, the company expects gross margin as a percent of revenue to increase.

Marketing, selling and administrative expenses are projected to grow in the low- to mid-single digits while research and development expenses are projected to grow in the low-double digits.

Other income is expected to be a net loss of between $150.0 and $200.0 million, and the tax rate is expected to be approximately 22 percent.

Cash flows are expected to be sufficient to fund capital expenditures of approximately $1.0 billion, anticipated business development activity and the company's dividend.

Longer-term Financial Commentary

The company reaffirmed its commitment to deliver low double-digit compound annual earnings per share growth between 2007 and 2011, excluding the potential impact of health care reform in the U.S.

Looking further out, the company also provided a general perspective on possible financial performance during the major patent expiry years of 2012 to 2014 and beyond.

During this time, the company anticipates annual revenue of at least $20.0 billion. Gross margins as a percent of revenue could be between 75 and 80 percent. Operating expenses, the sum of selling, general and administrative expenses and research and development expenses, as a percent of revenue could be in the mid 50s. The tax rate could be higher than today, possibly 25 percent.

Under this scenario, net income would exceed $3.0 billion and operating cash flow would exceed $4.0 billion. This level of operating cash flow would solidly position the company to fund research and development, capital expenditures and the dividend.

As the company plans for this challenging time period, it believes it will gene
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Reportlinker.com announces that ... in its catalogue: Wireless Opportunities ... Zigbee, UWB WWAN, WMAN, WLAN and other ... Kalorama Information,s Wireless Opportunities in ... UWB WWAN, WMAN, WLAN and other technologies) ...
(Date:8/20/2014)... , Aug. 20, 2014   Ventana ... Roche  Group, today announced that its VENTANA System ... marked in the European Union for routine pathology, ... system, consisting of VENTANA Virtuoso software coupled with ... iScan HT slide scanner, provides automated digital slide ...
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group ... and ablation device market will expand through ... treat atrial fibrillation (AF). The increasing acceptance ... for AF will spur adoption of premium-priced ... as advanced loop diagnostic catheters, cryoablation catheters ...
Breaking Medicine Technology:Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 2Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 4Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 5Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 6Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 7Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 8Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 9Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 10Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 11Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 12Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 13Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 14Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 15Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 16Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3
... Dec. 8 Halozyme Therapeutics, Inc.,(Nasdaq: HALO ... extracellular matrix, today announced that Roche has,dosed the first ... a,subcutaneous formulation using Enhanze Technology of a biologic directed ... payment under the,agreement. , ...
... Positive Opinion for TEMODAL(R) Intravenous Formulation and Oral TEMODAL ... EU Patients with Certain Primary Brain Tumors , ... Schering-Plough Corporation (NYSE: SGP ) today ... Use (CHMP) of the European Medicines Agency (EMEA) has ...
Cached Medicine Technology:Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target 2Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target 3Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target 4CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors 2CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors 3CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors 4CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors 5CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors 6
(Date:8/20/2014)... The non-small cell lung cancer (NSCLC) ... offing across the top 8 developed nations, from just ... USD 8 billion by 2020-end, posting a CAGR of ... to be driven by innovative therapies entering the squamous ... treatment, unlike the non-squamous segment. Thus, patients with SCC ...
(Date:8/20/2014)... Santa Rosa, CA (PRWEB) August 20, 2014 ... is the 12 per diode panel band perfect spectrum that ... plants are most likely to use during photosynthesis. A ... spectral bands is that they almost exclusively reside between 440-480 ... 620-680 on the red side of the spectrum. The KIND ...
(Date:8/20/2014)... Battle Creek, MI (PRWEB) August 20, 2014 ... an open-ended drug and alcohol treatment program that gets clients ... foundation in recovery they can believe in, is highlighting an ... that must be heeded by everyone who wants to understand ... “Many people are of the belief that drug abuse targets ...
(Date:8/20/2014)... 20, 2014 According to a ... "Multiplexed Diagnostics Market (Technologies: Very High, High, Medium, ... Disease Diagnosis, Oncology, Autoimmune Diseases, Cardiac, Allergies and ... Trends and Forecast, 2013 - 2019", the global ... billion in 2012 and is expected to grow ...
(Date:8/20/2014)... A survey of U.S. veterans receiving mental health services ... also significant room for improvement among all areas studied. ... 2009, found that patients with a substance use disorder ... health services. Those with substance abuse problems also were ... to them or respected their decisions. , The findings, ...
Breaking Medicine News(10 mins):Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 4Health News:Cheap LED Grow Lights Are Quickly Being Replaced by Premium Grow Lights 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Survey finds veterans generally satisfied with mental health care 2
... for 2009VANCOUVER, Feb. 19 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: ... reported its financial results for the fourth quarter ending December ... its guidance for 2009. Unless specified otherwise, all amounts are ... "2008 was a pivotal year for us as we concluded ...
... Defyrus Inc. today announced the signing an exclusive, ... the United Kingdom,s Defence Science and Technology Laboratory ... commercialization company. These patents form the intellectual property ... Defyrus and Ploughshare Innovation Ltd plan to expand ...
... Advisers, LLC (MCRA), the leading musculoskeletal consulting firm ... and reimbursement strategy development, announced today the signing ... to have reached this important milestone in the ... date are directly attributed to our best-in-class team ...
... continuing operations of $0.70, [excluding amortization], up 19.8% ... $0.65, up 18.3% - Net revenues of $24.1 ... (NYSE: CVS ), today announced record ... quarter and year ended December 31, 2008. (Logo: ...
... 2009 OutlookVIRGINIA BEACH, Va., Feb. 19, 2009 AMERIGROUP Corporation ... income for the fourth quarter of 2008 increased 20.0% to ... of $31.1 million, or $0.57 per diluted share, for the ... 31, 2008, the Company,s net loss was $50.7 million, or ...
... Free 6-Month Subscription to its Vulnerability Management and Endpoint Protection ... and Reduce TCO , ... Scottsdale, ... leader in security management, announced the launch of its global ...
Cached Medicine News:Health News:QLT Announces Fourth Quarter and Year End 2008 Results 2Health News:QLT Announces Fourth Quarter and Year End 2008 Results 3Health News:QLT Announces Fourth Quarter and Year End 2008 Results 4Health News:QLT Announces Fourth Quarter and Year End 2008 Results 5Health News:QLT Announces Fourth Quarter and Year End 2008 Results 6Health News:QLT Announces Fourth Quarter and Year End 2008 Results 7Health News:QLT Announces Fourth Quarter and Year End 2008 Results 8Health News:QLT Announces Fourth Quarter and Year End 2008 Results 9Health News:QLT Announces Fourth Quarter and Year End 2008 Results 10Health News:QLT Announces Fourth Quarter and Year End 2008 Results 11Health News:QLT Announces Fourth Quarter and Year End 2008 Results 12Health News:QLT Announces Fourth Quarter and Year End 2008 Results 13Health News:QLT Announces Fourth Quarter and Year End 2008 Results 14Health News:QLT Announces Fourth Quarter and Year End 2008 Results 15Health News:QLT Announces Fourth Quarter and Year End 2008 Results 16Health News:QLT Announces Fourth Quarter and Year End 2008 Results 17Health News:QLT Announces Fourth Quarter and Year End 2008 Results 18Health News:QLT Announces Fourth Quarter and Year End 2008 Results 19Health News:Vaccine patent portfolio licensed from UK Ministry of Defence 2Health News:Musculoskeletal Clinical Regulatory Advisers, LLC Announces Signing of its 100th Client 2Health News:CVS Caremark Reports Record Results in Fourth Quarter and Year 2008 2Health News:CVS Caremark Reports Record Results in Fourth Quarter and Year 2008 3Health News:CVS Caremark Reports Record Results in Fourth Quarter and Year 2008 4Health News:CVS Caremark Reports Record Results in Fourth Quarter and Year 2008 5Health News:CVS Caremark Reports Record Results in Fourth Quarter and Year 2008 6Health News:CVS Caremark Reports Record Results in Fourth Quarter and Year 2008 7Health News:CVS Caremark Reports Record Results in Fourth Quarter and Year 2008 8Health News:CVS Caremark Reports Record Results in Fourth Quarter and Year 2008 9Health News:CVS Caremark Reports Record Results in Fourth Quarter and Year 2008 10Health News:CVS Caremark Reports Record Results in Fourth Quarter and Year 2008 11Health News:CVS Caremark Reports Record Results in Fourth Quarter and Year 2008 12Health News:CVS Caremark Reports Record Results in Fourth Quarter and Year 2008 13Health News:CVS Caremark Reports Record Results in Fourth Quarter and Year 2008 14Health News:CVS Caremark Reports Record Results in Fourth Quarter and Year 2008 15Health News:CVS Caremark Reports Record Results in Fourth Quarter and Year 2008 16
... Calvin Klein Collection. Provocatively inspired for ... a bold outlook. Innovative structure: soft-sculpted ... technology enhances modern design. Technological sophistication ... enhance the face., ,The Calvin Klein ...
... Marc Jacobs is ... very first collection in ... unveiling a range of ... that are defined by ...
... new GUCCI DONNA eyewear collection celebrates the ... a vintage yet contemporary feel, the unmistakable ... new GUCCI UOMO optical and sunglass collection, ... classic lines with cutting-edge design that is ...
The Alexander McQueen eyewear collection focuses on a distinctive sophisticated style, with feminine lines, assertive shapes and original silhouettes....
Medicine Products: